CME vs LPLA

Head-to-Head Stock Analysis & Investment Rating

Last Updated: Aug 24, 2026

CME

37.7
AI Score
VS
LPLA Wins

LPLA

40.1
AI Score

Investment Advisor Scores

CME

Aug 24, 2026
38score
Recommendation
SELL

LPLA

Aug 24, 2026
40score
Recommendation
HOLD

AI Analyst Insights

Detailed Metrics Comparison

Metric CME LPLA Winner
Forward P/E 21.7865 13.5135 LPLA
PEG Ratio 4.68 0.4859 LPLA
Revenue Growth 0.8% 36.4% LPLA
Earnings Growth 2.5% 39.4% LPLA
Tradestie Score 37.7/100 40.1/100 LPLA
Profit Margin 63.4% 5.2% CME
Beta 1.00 1.00 Tie
Implied Volatility N/A N/A Tie
AI Recommendation SELL HOLD LPLA

Relative Price Performance (Last 90 Days)

CME 1M: +8.1% · 3M: -4.9% LPLA 1M: +11.8% · 3M: +25.5%

Current Technical Phase

CME

Neutral
Hold

Mixed signals - no dominant trend phase, RSI 65

RSI (14): 64.7 · Price: $274.98

LPLA

Markup
Hold / add on dips

Price above SMA50, rising 50-day trend (9.9% over 20 days), RSI 58

RSI (14): 58.4 · Price: $361.35

Fundamentals Snapshot

Metric CME LPLA
Market Cap
Forward P/E 21.3 12.1
Trailing P/E 22.6 28.4
Revenue (TTM)
Revenue Growth 0.0% 0.4%
Gross Margin 1.0% 0.3%
Operating Margin 0.7% 0.1%
EPS 11.97 12.47
Dividend Yield 0.02% 0.00%

Frequently Asked Questions

Based on our detailed analysis, LPLA is currently the stronger investment candidate, winning 6 of the key financial metrics based on our comprehensive scoring model.

We analyze revenue and earnings growth rates in the "Growth" section above. Generally, the company with higher year-over-year revenue and EPS growth is fostering better expansion. Check the table above for the specific growth percentages.

Valuation is determined by metrics like the P/E Ratio and PEG Ratio. A lower P/E typically suggests a stock is cheaper relative to its earnings. Refer to the "Valuation" section in our comparison table to see which stock currently trades at a more attractive multiple.